GT200600044A - Polimorfo cci-779 y su uso - Google Patents
Polimorfo cci-779 y su usoInfo
- Publication number
- GT200600044A GT200600044A GT200600044A GT200600044A GT200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A
- Authority
- GT
- Guatemala
- Prior art keywords
- cci
- polymorph
- hydrometil
- sirolimus
- rapamycin
- Prior art date
Links
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title abstract 2
- 229960000235 temsirolimus Drugs 0.000 title abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 2
- 229960002930 sirolimus Drugs 0.000 abstract 2
- 241000187391 Streptomyces hygroscopicus Species 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65137405P | 2005-02-09 | 2005-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200600044A true GT200600044A (es) | 2006-11-09 |
Family
ID=36570939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200600044A GT200600044A (es) | 2005-02-09 | 2006-02-07 | Polimorfo cci-779 y su uso |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7442707B2 (https=) |
| EP (1) | EP1856130A1 (https=) |
| JP (1) | JP2008530090A (https=) |
| KR (1) | KR20070107030A (https=) |
| CN (1) | CN101115759A (https=) |
| AR (1) | AR052479A1 (https=) |
| AU (1) | AU2006213061A1 (https=) |
| BR (1) | BRPI0607932A2 (https=) |
| CA (1) | CA2595766A1 (https=) |
| CR (1) | CR9257A (https=) |
| GT (1) | GT200600044A (https=) |
| IL (1) | IL184560A0 (https=) |
| MX (1) | MX2007009590A (https=) |
| NO (1) | NO20073725L (https=) |
| PE (1) | PE20060996A1 (https=) |
| RU (1) | RU2007129264A (https=) |
| TW (1) | TW200638932A (https=) |
| WO (1) | WO2006086172A1 (https=) |
| ZA (1) | ZA200706628B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8551512B2 (en) | 2004-03-22 | 2013-10-08 | Advanced Cardiovascular Systems, Inc. | Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS |
| BRPI0619592A2 (pt) * | 2005-12-07 | 2016-09-06 | Wyeth Corp | métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina |
| AR058282A1 (es) * | 2005-12-07 | 2008-01-30 | Wyeth Corp | Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer. |
| US7622578B2 (en) * | 2005-12-07 | 2009-11-24 | Wyeth | Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate |
| TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
| EP2380006A4 (en) * | 2009-01-21 | 2012-05-16 | Biocon Ltd | PROCESS FOR DETERMINING THE SIROLIMUS STABILITY AND METHOD FOR PRODUCING ITS STABLE FORM |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| CN109020995A (zh) * | 2017-06-12 | 2018-12-18 | 鲁南制药集团股份有限公司 | 一种替西罗莫司的晶型物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
| US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| BR0211986A (pt) * | 2001-08-22 | 2004-09-28 | Wyeth Corp | 29-enóis de rapamicina |
| MXPA04001523A (es) | 2001-08-22 | 2004-05-31 | Wyeth Corp | Dialdehidos de rapamicina. |
| WO2005010010A1 (en) | 2003-07-16 | 2005-02-03 | Wyeth | Cci-779 isomer c |
| KR20060057605A (ko) | 2003-08-07 | 2006-05-26 | 와이어쓰 | Ｃｃｉ-779의 위치선택적 합성 방법 |
| RU2345999C2 (ru) | 2003-09-03 | 2009-02-10 | Уайт | Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции |
| JP4224115B2 (ja) * | 2004-04-14 | 2009-02-12 | ワイス | ラパマイシン４２−エステル誘導体の位置特異的合成 |
-
2006
- 2006-01-25 CA CA002595766A patent/CA2595766A1/en not_active Abandoned
- 2006-01-25 RU RU2007129264/04A patent/RU2007129264A/ru not_active Application Discontinuation
- 2006-01-25 US US11/339,728 patent/US7442707B2/en not_active Expired - Fee Related
- 2006-01-25 WO PCT/US2006/003098 patent/WO2006086172A1/en not_active Ceased
- 2006-01-25 BR BRPI0607932A patent/BRPI0607932A2/pt not_active IP Right Cessation
- 2006-01-25 JP JP2007555124A patent/JP2008530090A/ja not_active Withdrawn
- 2006-01-25 CN CNA200680004408XA patent/CN101115759A/zh not_active Withdrawn
- 2006-01-25 MX MX2007009590A patent/MX2007009590A/es not_active Application Discontinuation
- 2006-01-25 AU AU2006213061A patent/AU2006213061A1/en not_active Abandoned
- 2006-01-25 EP EP06734012A patent/EP1856130A1/en not_active Withdrawn
- 2006-01-25 KR KR1020077018347A patent/KR20070107030A/ko not_active Withdrawn
- 2006-02-03 PE PE2006000136A patent/PE20060996A1/es not_active Application Discontinuation
- 2006-02-06 TW TW095103902A patent/TW200638932A/zh unknown
- 2006-02-07 GT GT200600044A patent/GT200600044A/es unknown
- 2006-02-08 AR ARP060100451A patent/AR052479A1/es unknown
-
2007
- 2007-07-12 IL IL184560A patent/IL184560A0/en unknown
- 2007-07-18 NO NO20073725A patent/NO20073725L/no not_active Application Discontinuation
- 2007-07-18 CR CR9257A patent/CR9257A/es not_active Application Discontinuation
- 2007-08-08 ZA ZA200706628A patent/ZA200706628B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2595766A1 (en) | 2006-08-17 |
| NO20073725L (no) | 2007-09-05 |
| AU2006213061A1 (en) | 2006-08-17 |
| US7442707B2 (en) | 2008-10-28 |
| AR052479A1 (es) | 2007-03-21 |
| MX2007009590A (es) | 2007-09-12 |
| CR9257A (es) | 2007-11-23 |
| PE20060996A1 (es) | 2006-11-13 |
| WO2006086172A1 (en) | 2006-08-17 |
| ZA200706628B (en) | 2010-01-27 |
| JP2008530090A (ja) | 2008-08-07 |
| TW200638932A (en) | 2006-11-16 |
| CN101115759A (zh) | 2008-01-30 |
| EP1856130A1 (en) | 2007-11-21 |
| KR20070107030A (ko) | 2007-11-06 |
| RU2007129264A (ru) | 2009-03-20 |
| BRPI0607932A2 (pt) | 2016-11-08 |
| US20060178392A1 (en) | 2006-08-10 |
| IL184560A0 (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007028135A3 (en) | Imidazopyridine compounds | |
| TW200510428A (en) | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions | |
| CL2010000320A1 (es) | Un compuesto 8-(1,3-dihidro-isoindol-2-ilmetil)-2,9-dihidro-1,2,7,9-tetraaza-fenalen-3-ona, como inhibidor de parp; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| EP2662353A3 (en) | Antibacterial agents | |
| CL2012000707A1 (es) | Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c. | |
| WO2007084728A3 (en) | 2-imino-benzimidazoles | |
| CL2012001027A1 (es) | Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek. | |
| WO2007061923A3 (en) | Glucokinase activators | |
| HN2009000784A (es) | Dihidropirazolonas sustituidas | |
| BRPI0613429A2 (pt) | inibidores de histona desacetilase | |
| CR20210251A (es) | Derivados de 2,3-dihidro-1h-pirrolo(3,4-c)piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
| CO6260093A2 (es) | Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal | |
| ECSP078060A (es) | 2,4-diamino-pirimidinas como inhibidores de aurora | |
| CR10628A (es) | Compuestos quimicos | |
| CO6390082A2 (es) | Compuestos organicos | |
| BR112012008889A2 (pt) | compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes | |
| WO2010056754A3 (en) | Inhibition of mammalian target of rapamycin | |
| ECSP099451A (es) | Compuestos de urea policíclicos antibacterianos | |
| ECSP088932A (es) | Nuevos compuestos químicos | |
| ECSP088536A (es) | DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR | |
| WO2008096001A8 (en) | Hcv inhibiting macrocyclic phenylcarbamates | |
| BRPI0810064B8 (pt) | compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos | |
| UY28695A1 (es) | Derivados de difenilazetidona | |
| PE20080138A1 (es) | Procesos para preparar conjugados de polietilen glicol solubles en agua de inmunosupresores macrolidos | |
| AR063310A1 (es) | Procesos para la sintesis de isomeros individuales de cci-779 monopeg |